AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01216189 — intervention group
Intervention type: RADIATION
Intervention: Preoperative radiotherapy
Description: Preoperative radiotherapy (RT) was administered as either short course (5Gy x5) or long-course (2Gy x25 or 1.8 Gy x25 with or without 3 fractions of boost to the primary tumor and radiologically malignant lymph nodes) treatment with or without concomitant or sequential chemotherapy. Oncological treatment was decided at a multidisciplinary team conference.
Study NCT03370978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: To communicate with intervention patients after discharge from the ED, we will use a bidirectional text messaging service provided by another physician's research group within the University of Iowa. The nurse navigator will enter the patient's study identification number, first and last name and cell phone onto a secure study website established by this research group.~Patients will, as previously mentioned, have had their cell phone number tested in the text messaging system prior to leaving the Emergency Department (this includes the control group).~Patient's will receive a text message 3 days, and 1 day, prior to their scheduled follow-up appointment with Family Medicine (this appointment having been scheduled through the Emergency Department Nurse Navigators). Each text message will remind the patient of the date/time of their appointment, and provide them a link containing a map with the location of their appointment.
Study NCT03651570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTSD Coach
Description: PTSD Coach is a mobile mental health app that addresses the issue of mental health and stigma which can be used as a stand-alone education and symptom management and contains 4 modules: 1) Learn- Module, 2) Self- Assessment-Module, 3) Manage Symptoms-Module and 4) Find Support-Module.
Study NCT03651570 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Game application
Description: This control condition is important to control for distraction (attention on something pleasant or a task) and the human factor involved in usage prompting (i.e., same exposure time + contacts with personnel), since either distraction or the human contact with staff may, alone, lower anxiety
Study NCT00513916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy isoflavones
Description: High or low dose of soy isoflavones in the diet.
Study NCT00513916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: soy isoflavones
Description: High or low dose of soy isoflavones in the diet.
Study NCT04623632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominus plane block
Description: transversus abdominus plane block using 40 ml of bupivacaine 0.25%
Study NCT04623632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transversus abdominus plane placebo
Description: injection of 40 ml of normal saline in the transversus abdominus plane
Study NCT03352037 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET scan
Description: Patients with known pancreatic cystic lesions requiring MR imaging for lesion characterization for clinical evaluation will be recruited to undergo 18F-FDG PET/MR imaging after written informed consent.
Study NCT03636893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOT Chemotherapy
Description: 5-FU+Leucovorin+Docetaxel+Oxaliplatin
Study NCT03636893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOX Chemotherapy
Description: Oxaliplatin+Tegafur gimeracil oteracil potassium capsule (TGO)
Study NCT01301027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 15mg/day pioglitazone for 2 weeks, then 30mg/day pioglitazone for the remaining 24 weeks
Study NCT01301027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill a day for 26 weeks
Study NCT00541385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyronaridine artesunate
Description: The strength of the granule formulation is 60:20 mg pyronaridine artesunate per sachet. Depending on their body weight, patients will receive between 1 to 3 pyronaridine artesunate sachets per day, for 3 consecutive days The actual dose-range covered by this regimen is 7.0:2.3 mg/kg to 13.3:4.4 mg/kg pyronaridine artesunate, which has shown to be effective and safe in the phase II studies conducted in children and adults.
Study NCT00541385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arthemeter lumefantrine
Description: The strength of the tablet is 20 mg artemether and 120 mg lumefantrine. Depending on their body weight, patients will receive either 1 or 2 crushed tablets twice a day (≥5 to \<15 = 1 tablet, 15 to \<25 kg = 2 tablets), for 3 consecutive days.
Study NCT04072900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peptide
Description: 4 x 3 mg all the peptides given on days 84，87，91，98，105，133，and 161
Study NCT04072900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1
Description: 3mg/kg, ivgtt, Q2w
Study NCT04072900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Description: 3μg/kg given on Days 81，82，83，95，96，97，102，103，104，130，131，132，158，159，and 160
Study NCT04072900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% Topical Cream
Description: topical application on the injection site 6 hours before each NeoAntigen peptides injection
Study NCT02572908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sourdough wheat bread
Study NCT02572908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular yeast baked toast bread
Study NCT02572908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten-free diet
Description: Gluten-free diet excluding even oats and buckwheat. Rice, quinoa, corn and potato allowed as grains/pseudo-grains
Study NCT02572908 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gluten-free diet
Description: Gluten-free diet excluding even oats and buckwheat. Rice, quinoa, corn and potato allowed as grains/pseudo-grains
Study NCT02572908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gluten-free diet
Description: Gluten-free diet excluding even oats and buckwheat. Rice, quinoa, corn and potato allowed as grains/pseudo-grains
Study NCT03265314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LeadHer
Description: The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
Study NCT03265314 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sassy Science
Description: The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
Study NCT05533736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community based strategy to follow-up pactientes with Cutaneous Leishmaniasis
Description: Community Health leaders follow patients using the Guaral+ST app at final of treatment, and on days 90 and 180 after initiating the treatment.
Study NCT02144896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle splinting
Description: Ankle dorsiflexion splinting will be performed 30 minutes per day, 5 days per week for 4 weeks.
Study NCT02643446 — intervention group
Intervention type: BIOLOGICAL
Intervention: IPV
Description: IPV will be vaccinated at 2 months of age act as the first dose of poliovirus vaccine in the study group1 to group 4,group8 to group 11. IPV will be given at 3 month of age act as second vaccine in group 8,9,12
Study NCT02643446 — intervention group
Intervention type: BIOLOGICAL
Intervention: OPV
Description: OPV will be vaccinated at 3 and 4 months of age, act as the second and third dose of poliovirus vaccine in the study group 1 to group 4,group 10 to group 11.~OPV will be vaccinated at 2, 3 and 4 months of age act as the full three primary immunization doses of polio virus vaccine in the study group 5 to group 7.
Study NCT02353975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: SHR3824 tablet,10mg, fasting conditions and high fat, high calorie breakfast.
Study NCT03715348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prothrombin Complex Concentrate (PCC)
Description: PCC is a blood product produced through pooling of thousands of human plasmas, which is then treated to inactivate enveloped viruses. From the pooled plasma, vitamin K dependent clotting factors (factors II, VII, IX and X, and protein C and protein S), are selected to produce the concentrated form called PCC.
Study NCT03715348 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: Fresh Frozen Plasma a blood component manufactured from whole blood collection.
Study NCT02765750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intraoperative positive messages
Description: The message You are in the operating room. Everything is going very well. When you wake up you will be very calm, you will not feel pain and you will not have nausea will be played in greek language by headphones to the patient when the Bispectral Index (BIS) is 40-60.
Study NCT02765750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intraoperative positive messages
Description: The message You are in the operating room. Everything is going very well. When you wake up you will be very calm, you will not feel pain and you will not have nausea will be played in greek language by headphones to the patient when the Bispectral Index (BIS) is 20-40.
Study NCT02765750 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No message
Description: The headphones will be placed on patient's ears but no message will be played.
Study NCT03387618 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Digital PET/CT imaging
Description: Next generation PET/CT imaging
Study NCT04411667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octagam
Description: Standard of Care plus Octagam infusion for 3 days.
Study NCT04355169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Oral tablet
Study NCT04355169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study NCT00135551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin receptor blockers
Description: benidipine+angiotensin receptor blocker, titlation scheme
Study NCT00135551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: β-blockers
Description: benidipine+β-blockers, titlation scheme
Study NCT00135551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiazide diuretics
Description: benidipie+thiazide diuretics, titlation scheme
Study NCT00679900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eplivanserin (SR46349)
Description: 5 mg/day
Study NCT00679900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lormetazepam
Description: 1 mg/day
Study NCT04205877 — intervention group
Intervention type: DEVICE
Intervention: Transcatheter PDA Closure
Description: Device utilized for closure of PDA, study is to help assure continued safety and effectiveness of FDA approved Amplatzer Piccolo Occluder device as well as other devices used off label for PDA closure in premature infants less than 2 kg at the time of device implant.
Study NCT02064023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insulin pump
Description: subjects in the experimental arm will administer insulin using a pump
Study NCT02064023 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multiple daily insulin injection
Description: Subjects will continue with usual insulin injections
Study NCT03807206 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Patient questionnaire
Study NCT01840982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed grain 1
Description: All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
Study NCT01840982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed grain 2
Description: All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
Study NCT01840982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: White rice
Description: All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
Study NCT01840982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose solution
Description: All test foods contained 50 g available carbohydrate from the test food products.
Study NCT00690781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pulse casein feeding during energy restriction
Description: Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
Study NCT00690781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spread casein feeding during energy restriction
Description: Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
Study NCT00690781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pulse milk soluble protein feeding during energy restriction
Description: Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
Study NCT00690781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spread milk soluble protein feeding during energy restriction
Description: Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
Study NCT02056587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.
Study NCT03780166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib administered orally once daily at the cohort-specified dose level.
Study NCT03537521 — intervention group
Intervention type: PROCEDURE
Intervention: Urgent surgery which can not be postponed to the next 24 hrs
Description: The urgent surgical intervention is not part of the registry protocol. The intervention is the acute event that leads to enrollment in the registry. It might be e.g. the surgical treatment of a trauma, fall, acute abdomen, appendicitis or anything else.
Study NCT04593537 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study, no intervention is involved
Study NCT04677088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR-T cells
Description: Patients will receive 1 x 10\^4 cells/kg to 5 x 10\^6 cells/kg bodyweight of TCR redirected T cells by IV infusion.
Study NCT04379895 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Pulsed or heated RF ablation of the genicular nerves will be done as an Acceptable treatment for OA of the knee
Study NCT00493129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontak (Denileukin Diftitox)
Description: 9 µg/kg by vein Days 1-5 of a 21 day cycle.
Study NCT00544297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 gel
Description: Two day application, 0.05%
Study NCT03257059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: Glutinous rice (75 grams of available carbohydrate)
Study NCT03257059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Breakfast
Description: No food to be served in the morning
Study NCT02214134 — intervention group
Intervention type: GENETIC
Intervention: Tumour markers testing
Study NCT02275234 — intervention group
Intervention type: OTHER
Intervention: Psychological intervention
Description: Psychological support via clinic visit, helpline and telephone calls
Study NCT01577888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave System Treatment
Description: Shockwave System Treatment during vascular disease intervention.
Study NCT02357368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Description: DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15.
Study NCT02357368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etonogestrel implant (Eng-Implant)
Description: A standard nexplanon rod implant will be placed at study week 3 by a trained clinician.
Study NCT02357368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine device (Lng-IUD)
Description: A standard Mirena IUD will be placed at study week 3 by a trained clinician.
Study NCT02357368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ParaGard® T 380A Intrauterine Copper Contraceptive
Description: A standard ParaGuard IUD will be placed at study week 3 by a trained clinician.
Study NCT01871935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Anaesthesia with remifentanil/propofol.
Study NCT01871935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Anaesthesia with sufentanil/propofol
Study NCT04082793 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy with mandibular exercises
Description: Low-level laser therapy (BMI 1005 Laser 2200) Wavelength: 658 nm Power: 100 MW Energy density: 4J/cm2 Dose administered: 4J Mode: Pulsed Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions/week on alternating days for 12 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement of the jaw Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetitions X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day
Study NCT04082793 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sonophoresis with mandibular exercises
Description: Ultrasound (BM1-1039) Ultrasonic massage with Diclofenac gel Frequency: 1.0 MHz Mode: Continuous Intensity: 0.8 to 1.5 W/cm2~Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions per week on alternating days for 8 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetition X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day
Study NCT03831750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress Reduction Intervention
Description: The tri-component intervention is comprised of guided videos for breath-work (5-15 min), stretching (5-15 min), and meditation (10-30 min). The intervention will be delivered online via an access restricted website.
Study NCT03895840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilretta
Description: Zilretta (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee osteoarthritis.
Study NCT03074240 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAPB Group
Description: Subjects allocated to the TAPB group will be monitored for instances of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia will be compared.
Study NCT03074240 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RSB Group
Description: Subjects allocated to the RSB group will be monitored for instances of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia will be compared.
Study NCT03074240 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conversion to general anesthesia
Description: For those who do not respond to TAPB or RSB to allow for completion of the intended procedure.
Study NCT03382353 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Description: Daily consumption of Tramiprosate (100 mg) for 1 year